




CONTRIBUTED PHOTOS
From left are Vance Embry, with Shaw Industries and the United Way Young Leaders Society co-chair, and Josh Young, with Brown Industries, the winner of the Lip Sync Battle dressed as Vanilla Ice.

Young Leaders host lip sync battle

SUBMITTED BY THE UNITED WAY

Recently the United Way Young Leaders Society hosted a Lip Sync Battle at the Dalton Distillery to celebrate the group's tenth anniversary in northwest Georgia. Competitors included Chad Boyd, Seth Brown, Danny Contreras, Chad Guinn, Wes Harness,

Dana Lake, Jennifer Latour, Maria Rochelle, Bob Sheth, Brittany Wade, Eric Ward and Josh Young. The Young Leaders Society has 322 members who make an annual household gift of \$365 or more to United Way. It is an organization of leaders 45 and under who strive to make great things happen in the community.



Standing from left are Chad Boyd, Chad Guinn and Wes Harness, and kneeling at the front is Seth Brown, all with Marketing Alliance, as they perform Queen's "Bohemian Rhapsody."

Volunteers sought as race to develop a Zika vaccine heats up

BY LAUREN NEERGAARD
AP Medical Writer

WASHINGTON — Wanted: Volunteers willing to be infected with the Zika virus for science.

It may sound bizarre, but researchers are planning just such a study — this winter, when mosquitoes aren't biting — to help speed development of much-needed Zika vaccines.

The quest for a vaccine began less than a year ago as Brazil's massive outbreak revealed that Zika, once dismissed as a nuisance virus, can harm a fetus' brain if a woman is infected during pregnancy.

Now, researchers in the United States have begun safety testing of two vaccine candidates, and more experimental shots are poised to enter that preliminary testing soon. Any that seem promising will have to be tested in thousands of people in parts of Latin America and the Caribbean that are hard-hit by the mosquito-borne virus — the only way to prove if an experimental vaccine really protects.

Even if all goes well, a vaccine wouldn't be available for general use any time soon.

But a different kind of research also can offer clues for vaccine development. It's called a human challenge study, when healthy — and nonpregnant — people agree to be injected deliberately with a virus, mimicking natural infection while scientists track how their bodies react.

The first question is even more basic: How much of the virus does it take to infect someone?

If government regulators agree, researchers could find out by injecting paid volunteers with different amounts of lab-grown Zika virus as early as December in a Baltimore hospital. That information will help the researchers later, when they're ready to test an experimental Zika vaccine.

"We're looking at these human challenge protocols not only as an important step in vaccine development but as a means to learn more about Zika," said Dr. Anna Durbin of Johns Hopkins Bloomberg School of Public Health, who is leading the work. "We can look at things that you just can't do in someone who's naturally infected."

Some questions and answers about the development of Zika vaccines:

Q: Which potential vaccines are first in line?

A: Two so-called DNA vaccines have begun preliminary safety testing, one made by the National Institutes of



AP PHOTO

This photo provided by The National Institute of Allergy and Infectious Diseases shows a healthy volunteer receiving the NIAID Zika virus investigational DNA vaccine as part of an early-stage trial to test the vaccine's safety and immunogenicity. This is the first administration of this vaccine in a human.

Health and the other by Pennsylvania-based Inovio Pharmaceuticals.

They mark a new kind of technology. Traditionally, vaccines are made using a dead or weakened virus to train the body's immune system to recognize that infection and fight it off. DNA vaccines may be easier to make. Scientists used a circular piece of DNA, called a "plasmid," to carry genes that prompt the body itself to produce certain Zika virus proteins, alerting the immune system.

That piece of trickery worked in animals. The phase 1 studies in dozens of people will check for safety, and whether the vaccinations rev up human immunity enough to justify further tests.

Q: What else is in the pipeline?

A: "We are right now in a race of time to get the best vaccine," said Dr. Anthony Fauci, director of NIH's National Institute of Allergy and Infectious Diseases.

Multiple candidates are important as there's no way to predict which kind will work best. The DNA vaccines simply were ready for human testing first.

In October, safety tests are set to begin using the more traditional killed-virus vaccine, developed by the Walter Reed Army Institute of Research.

The NIH also is developing a vaccine using live-but-weakened virus, the type thought to trigger particularly long-lasting immune protection. That's the kind used to protect against rubella, which back in the 1960s caused an epidemic of birth defects.

Q: If the first candidates are safe, what happens next?

A: Fauci expects to open next-step studies in January, enrolling 2,400 to 5,000 people in areas where Zika still is spreading widely to test if the vaccinated are less likely than the unvaccinated to become infected.

Q: Are vaccines aimed at pregnant women?

A: Not at this point. It's hard to test new products during pregnancy. Plus, a fetus can be vulnerable to Zika even before a woman realizes she's pregnant.

The goal instead is to vaccinate women of child-bearing age and their sexual partners — because Zika also can be transmitted through sex — well before pregnancy ever occurs.

Q: Where do the human challenge studies come in?

A: Jabbing someone with Zika is faster than waiting around for a mosquito to bite them to see if an experimental vaccine provides protection. But first Durbin must find what dose of Zika causes infection, to be sure she's giving a vaccine enough of a challenge.

That's what the study planned for December would do. Volunteers given different amounts of Zika would be kept in a Hopkins hospital unit for 12 days, to be sure the virus had cleared the bloodstream, and would have to agree to use condoms for a while afterward to avoid any possibility of sexual transmission. Because Zika usually causes few if any symptoms, those infected might expect a rash or low fever.

The second round of the research would recruit volunteers who'd received an experimental vaccine, trying to infect them with Zika six months after their shot.

The extra benefit: Tracking people from the moment they're exposed to Zika also could shed important new light on how the virus affects the body — such as how long it's infectious in blood, semen and other bodily fluids, and just how the immune system fights it off.

Q: Has this been done before?

A: Human challenge studies are rare because they're difficult to perform and expensive. But Durbin recently did just such research to test a potential vaccine against dengue, a dangerous cousin of Zika, and doesn't expect difficulty recruiting volunteers for the Zika study once regulators are satisfied it can be conducted safely.

Q: What about the fight over federal funding for Zika?

A: In February, the Obama administration requested \$1.9 billion for the nation's fight against Zika, including vaccine development, but Congress hasn't approved any of it. With existing money running out, federal health officials are taking funds meant for other diseases to get by until the end of the year — but Fauci said NIH alone will need \$196 million more in 2017 to avoid delays in the vaccine research.

DOJ to sue state over 'psychoeducational' schools

ATLANTA (AP) — The U.S. Department of Justice says it will file a lawsuit claiming the state of Georgia violated the civil rights of disabled students.

The Atlanta Journal-Constitution reported Wednesday the justice department is accusing the state of violating the Americans with Disabilities Act regarding students

assigned to the Georgia Network for Educational and Therapeutic Support.

The act requires disabled students to receive the same level of education as children who are not impaired.

Federal and state officials swapped proposals for several months on the approach of the state's so-called

"psychoeducational" schools. But neither side was unable to come to terms on the key issue of whether Georgia could continue segregating children with behavioral and emotional disabilities.

Last year, the justice department notified state officials that an investigation found illegal segregation in GNETS.

Pleasant Valley Personal Care

Choose with Confidence

The love, kindness, patience, and talents you shared with my mother, Billie, are unforgettable.

~Bruce Satterfield

We appreciate Pleasant Valley 's wonderful staff more than you know.

~Bob & Melanie Reichley

We wouldn't want to be anywhere else.

~Ann Coats

**Studio \$2200/month
Suite \$2600/month**

706-259-3094

054000214056

Attention all Licensed Real Estate Agents!!!

Come and learn about selling HUD Homes.....this class will be offered at 12:30pm, August 23rd at Peggy Holmes Realty, Inc located at 2004 South Dixie Hwy Dalton, Ga 30720. Call Peggy Holmes Realty, Inc. 706-278-5000 to reserve your space.

054000214053

Varnell Cafe

Good Home Cooking

OPEN TUES - FRI 6AM - 2PM
SATURDAY 6AM - 1PM

We would like to welcome Bert Beck as our New Kitchen Manager

GOOD HOME COOKING

Now Serving Breakfast All Day On Saturday

Dine In Drive Thru Call Ahead

Like us on Facebook

3442 Cleveland Rd. • Dalton • (706)259-5355

054000214053